Marinus Pharmaceuticals News

Marinus Pharma Analyst Ratings

BenzingaJun 18 06:26 ET

Buy Rating Affirmed: Marinus Pharmaceuticals' Advancements and Long-term Patent Protection Signal Strong Prospects

TipRanksMay 17 09:21 ET

Buy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost Management

TipRanksMay 10 01:30 ET

Marinus Pharma Analyst Ratings

BenzingaMay 9 06:49 ET

Buy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug Trials

TipRanksMay 8 12:20 ET

Marinus Pharma Analyst Ratings

BenzingaMay 7 10:00 ET

Marinus Pharma Analyst Ratings

BenzingaApr 16 12:01 ET

Marinus Pharma Analyst Ratings

BenzingaApr 15 14:52 ET

Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health

TipRanksApr 15 13:30 ET

Marinus Pharma Analyst Ratings

BenzingaApr 10 09:44 ET

Buy Rating Affirmed for Marinus Pharmaceuticals With Promising Outlook for Ganaxolone in RSE Treatment

TipRanksMar 26 06:25 ET

Marinus Pharma Analyst Ratings

BenzingaMar 26 06:11 ET

Marinus Pharmaceuticals Earns Buy Rating From Analyst on Strong Sales and Promising Pipeline

TipRanksMar 6 23:20 ET

Marinus Pharma Analyst Ratings

BenzingaMar 6 07:37 ET

Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential

TipRanksMar 6 00:00 ET

Buy Rating Affirmed for Marinus Pharmaceuticals Amid Strong Q4 Sales and Promising Clinical Trials

TipRanksJan 4 09:45 ET

RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating

MT NewswiresJan 3 07:40 ET

Marinus Pharma Analyst Ratings

BenzingaDec 5, 2023 06:42 ET

Hold Rating on Marinus Pharmaceuticals: Delays, Opportunities, and Challenges in Clinical Trials

TipRanksNov 9, 2023 11:54 ET

Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25

BenzingaNov 8, 2023 10:11 ET